Subscribe
jackpress / Shutterstock.com
30 October 2025NewsAmericas

Novo Nordisk counters rival with $9bn bid for obesity drug developer

Danish pharma giant sweetens offer for hot peptide therapeutics company, aiming to cement its market position amid an intensifying GLP-1 patent race.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly strikes again in weight-loss drugs fight
29 July 2025   Texas pharmacy accused of mass-producing unapproved tirzepatide drugs | Lilly claimed pharmacy falsely marketed copycat versions of Mounjaro and Zepbound as safe and effective | It warned of “conducting a mass testing experiment on consumers without safety controls or informed consent”.
Americas
Novo Nordisk patent lapse opens door for Canadian Ozempic generics
17 June 2025   Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.
Big Pharma
Novo Nordisk strikes again over Wegovy generic
11 March 2025   The multinational claims Mylan Pharmaceuticals’ generic of its blockbuster weight loss drug infringes another new patent | Complaint similar but separate to previous lawsuit against Mylan and Sun Pharma.


Editor's picks

Why AI is changing the patent rules faster than anyone can keep up
Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025

Editor's picks

Americas
Why AI is changing the patent rules faster than anyone can keep up
24 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025

More features

‘We're being attacked from all sides’: Thermo Fisher Scientific counsel
China trademarks rankings reveal new entries, hidden gems and big brands
Edwards defends key heart valve product from infringement threat
Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?
The hidden code in life sciences deals
Why AI is changing the patent rules faster than anyone can keep up
LSPN panel unpacks critical IP risks in deal-making
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order